Antihypertensive Treatment in Masked Hypertension (NCT02893358) | Clinical Trial Compass
CompletedPhase 4
Antihypertensive Treatment in Masked Hypertension
China320 participantsStarted 2017-02-14
Plain-language summary
The primary purpose of the study is to estimate the target organ protection after 12 months of antihypertensive treatment in masked hypertension patients with at least one kind of target organ damage (left ventricular hypertrophy, large arterial stiffness and microalbuminuria). Improvement was defined as the relevant parameter back to normal or declined at least 20%.
The secondary objectives include: blood pressure lowering effect, target organ damage parameters improvement, and the incidence rate of all cause death and cardiovascular events (stroke and myocardia infraction).
Who can participate
Age range30 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 30-70 years old
✓. Masked hypertension patients, defined as clinic BP\<140/90 mmHg, while 24h ambulatory BP ≥130/80 mmHg and (or) daytime BP ≥135/85 mmHg and (or) nighttime BP ≥120/70 mmHg
✓. Combined with at least one kind of target organ damage: left ventricular hypertrophy (Cornell voltage combination ≥2440mm·ms or Sokolow-Lyon index ≥4.0mv for male and 3.5mv for female), large arterial stiffness (brachial-ankle pulse wave velocity ≥1400cm/s) and microalbuminuria (twice random urine microalbuminuria/creatinine ratio ≥2.5mg/mmol for male and 3.5mg/mmol for female).
✓. Didn't use any anti-hypertension drugs within 2 weeks
✓. Be willing to participate in the trials and able to finish clinic visits
Exclusion criteria
✕. Under antihypertensive treatment
✕. Secondary hypertension
✕. Taking other medications that may influence BP
✕. Sleep apnea syndrome
✕. Diabetes combined with microalbuminuria
✕. Renal parenchymal disease, such as chronic nephritis, polycystic kidney
✕. Occurrence of coronary heart disease, myocardial infraction or stroke within 6 months
What they're measuring
1
Improvement rate of target organ damage (left ventricular hypertrophy, large arterial stiffness and microalbuminuria)